Blueprint Medicines Reports Second Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Blueprint Medicines (BPMC) Misses Q2 EPS by 44c
August 2, 2022 7:06 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.68), $0.44 worse than the analyst estimate of ($2.24). Revenue for the quarter came in at $36.5 million versus the consensus estimate of $36.85 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More


